60 Degrees Pharmaceuticals Stock (NASDAQ:SXTP)


RevenueOwnershipFinancialsChart

Previous Close

$1.03

52W Range

$1.01 - $18.36

50D Avg

$1.46

200D Avg

$3.82

Market Cap

$1.92M

Avg Vol (3M)

$737.14K

Beta

5.27

Div Yield

-

SXTP Company Profile


60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

3

IPO Date

Jul 12, 2023

Website

SXTP Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceJun 24Mar 24
Product$124.97K-
Service$10.79K$10.79K

Fiscal year ends in Dec 23 | Currency in USD

SXTP Financial Summary


Dec 23Dec 22Dec 21
Revenue$253.57K$223.21K$1.16M
Operating Income$-5.15M$-1.75M$-1.12M
Net Income$-3.70M$-6.18M$-4.25M
EBITDA$-5.05M$-1.71M$-1.01M
Basic EPS$-0.64$-1.07$-0.74
Diluted EPS$-0.64$-1.07$-0.74

Fiscal year ends in Dec 23 | Currency in USD